Company Novus Therapeutics, Inc. Nasdaq
Equities
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 51 | 01/20/01 | |
Paul Little
DFI | Director of Finance/CFO | 60 | 15/21/15 |
Steven N. Perrin
PSD | President | 59 | 14/20/14 |
Eliezer Katz
CTO | Chief Tech/Sci/R&D Officer | - | 23/23/23 |
John Herberger
CTO | Chief Tech/Sci/R&D Officer | - | 01/22/01 |
Bryan E. Smith
CMP | Compliance Officer | 45 | 19/21/19 |
David Hovland
LAW | General Counsel | - | 19/21/19 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Keith Katkin
CHM | Chairman | 52 | 01/17/01 |
Walter C. Ogier
BRD | Director/Board Member | 67 | 14/20/14 |
John S. McBride
BRD | Director/Board Member | 72 | 01/17/01 |
Steven N. Perrin
PSD | President | 59 | 14/20/14 |
Chief Executive Officer | 51 | 01/20/01 | |
James Robinson
BRD | Director/Board Member | 54 | 01/23/01 |
June Lee
BRD | Director/Board Member | 58 | 09/20/09 |
Jan Hillson
BRD | Director/Board Member | 71 | 02/21/02 |
Allan Kirk
BRD | Director/Board Member | - | 02/23/02 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 110,086 | 0 | 0 | 94.57 % |
Stock B | 1 | 24,813,130 | 23,466,868 ( 94.57 %) | 0 | |
Stock C | 0 | 4,422 | 0 | 0 |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+2.97% | 108B | |
+10.21% | 104B | |
+2.62% | 22.33B | |
-12.77% | 22.19B | |
-7.05% | 18.69B | |
-37.64% | 17.74B | |
-6.50% | 17.64B | |
+6.00% | 14.05B | |
+37.20% | 12.51B |